<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39398431</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">3005-7590</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>IJTLD open</Title><ISOAbbreviation>IJTLD Open</ISOAbbreviation></Journal><ArticleTitle>Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>448</EndPage><MedlinePgn>443-448</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5588/ijtldopen.24.0180</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">An 'indeterminate' interferon-gamma release assay (IGRA) result used in the diagnosis of latent TB infection (LTBI) is most commonly due to an inadequate control (or 'mitogen') response, which may reflect underlying T-cell dysfunction.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a single-centre, retrospective study on COVID-19 patients admitted to a tertiary referral hospital who had IGRA testing conducted over a 5-month period. The primary outcomes included predictors of indeterminate IGRA results and associations with COVID-19 outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 181 patients were included for analysis. Approximately one-third of patients hospitalised with COVID-19 with IGRA testing performed (60/181) had an indeterminate result. The likelihood of an indeterminate IGRA was increased in patients with a history of solid organ transplant and a higher severity of COVID-19 at the time of testing. An indeterminate IGRA was associated with a higher risk of severe COVID-19 and a higher risk of admission to the ICU during admission to the hospital. No difference in mortality between the two subgroups was found.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our study demonstrated that COVID-19 patients on immunosuppression had a high likelihood of an indeterminate IGRA result, which was associated with markers of disease severity and immunosuppression. In this cohort, an indeterminate result was associated with worse COVID-19 outcomes.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>S J W</ForeName><Initials>SJW</Initials><AffiliationInfo><Affiliation>Department of Respiratory, Sleep and Mycobacterial Medicine, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metro South Clinical Tuberculosis Service, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eather</LastName><ForeName>G W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>Department of Respiratory, Sleep and Mycobacterial Medicine, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Metro South Clinical Tuberculosis Service, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qureshi</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Respiratory, Sleep and Mycobacterial Medicine, Princess Alexandra Hospital, Metro South Health, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>J R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>QCIF Bioinformatics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>IJTLD Open</MedlineTA><NlmUniqueID>9918803487706676</NlmUniqueID><ISSNLinking>3005-7590</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="fre"><AbstractText Label="CONTEXTE" NlmCategory="BACKGROUND">Un résultat « indéterminé » du test de libération d'interféron-gamma (IGRA, pour l’anglais « <i>interferon-gamma release assay</i> »), employé pour diagnostiquer l'infection tuberculeuse latente (LTBI pour l’anglais « <i>latent TB infection</i> »), est généralement attribué à une réponse de contrôle insuffisante (ou « mitogène »), ce qui peut indiquer un dysfonctionnement sous-jacent des cellules T.</AbstractText><AbstractText Label="MÉTHODES" NlmCategory="UNASSIGNED">Nous avons mené une étude rétrospective unicentrique portant sur des patients atteints de COVID-19, admis dans un hôpital de référence de niveau tertiaire, ayant subi un test IGRA sur une durée de 5 mois. Les résultats principaux ont mis en évidence les facteurs prédictifs des résultats IGRA indéterminés ainsi que les corrélations avec les résultats liés au COVID-19.</AbstractText><AbstractText Label="RÉSULTATS" NlmCategory="UNASSIGNED">Au total, 181 patients ont été inclus dans l'analyse. Environ un tiers des patients hospitalisés pour COVID-19 ayant subi un test IGRA (60 sur 181) ont présenté un résultat indéterminé. La probabilité d'obtenir un résultat IGRA indéterminé était plus élevée chez les patients ayant des antécédents de greffe d'organe solide et ceux présentant une sévérité accrue de la maladie au moment du test. Un résultat IGRA indéterminé était corrélé à un risque accru de COVID-19 sévère ainsi qu'à une probabilité plus élevée d'admission en unité de soins intensifs lors de l'hospitalisation. Aucune différence significative de mortalité n'a été observée entre les deux sous-groupes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Notre recherche a révélé que les patients souffrant de COVID-19 et recevant un traitement immunosuppresseur présentaient une probabilité élevée d'obtenir un résultat IGRA indéterminé, ce qui était corrélé avec des indicateurs de gravité de la maladie et d'immunosuppression. Au sein de cette cohorte, un résultat indéterminé était lié à des issues moins favorables dans le contexte de l'étude sur le COVID-19.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">IGRA</Keyword><Keyword MajorTopicYN="N">immunosuppression</Keyword></KeywordList><CoiStatement>Conflict of interest: none declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>16</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39398431</ArticleId><ArticleId IdType="pmc">PMC11467851</ArticleId><ArticleId IdType="doi">10.5588/ijtldopen.24.0180</ArticleId><ArticleId IdType="pii">24-0180</ArticleId><ArticleId IdType="sici">ijtldopen.24.0180</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Redelman-Sidi G, Sepkowitz KA. IFN-γ release assays in the diagnosis of latent tuberculosis infection among immunocompromised adults. Am J Respir Crit Care Med. 2013;188(4):422–431.</Citation><ArticleIdList><ArticleId IdType="pubmed">23262514</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, et al. . Frequency and significance of indeterminate and borderline Quantiferon Gold TB IGRA results. Eur Respir J. 2017;50(4).</Citation><ArticleIdList><ArticleId IdType="pubmed">29074546</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre A, et al. . Preliminary observations on IGRA testing for TB infection in patients with severe COVID-19 eligible for immunosuppressive therapy. Respir Med. 2020;175:106204.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7645275</ArticleId><ArticleId IdType="pubmed">33186846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sester M, et al. . Risk assessment of tuberculosis in immunocompromised patients. A TBNET study. Am J Respir Crit Care Med. 2014;190(10):1168–1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">25303140</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L, et al. . Hypothesis for potential pathogenesis of SARS-CoV-2 infection–a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020;9(1):727–732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7170333</ArticleId><ArticleId IdType="pubmed">32196410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadotti AC, et al. . IFN-γ is an independent risk factor associated with mortality in patients with moderate and severe COVID-19 infection. Virus Res. 2020;289:198171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7510544</ArticleId><ArticleId IdType="pubmed">32979474</ArticleId></ArticleIdList></Reference><Reference><Citation>Bordallo B, et al. . Severe COVID-19: what have we learned with the immunopathogenesis? Adv Rheumatol. 2020;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7506814</ArticleId><ArticleId IdType="pubmed">32962761</ArticleId></ArticleIdList></Reference><Reference><Citation>Coppock D, et al. . Interferon gamma release assay mitogen responses in COVID-19. Infect Dis Clin Pract. 2022;30(1):e1085.</Citation></Reference><Reference><Citation>Chatterjee K, et al. . Steroids in COVID-19: An overview. Cleve Clin J Med. 2020;8:1–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32819962</ArticleId></ArticleIdList></Reference><Reference><Citation>Soy M, et al. . Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol. 2020;39(7):2085–2094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7260446</ArticleId><ArticleId IdType="pubmed">32474885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadolini M, et al. . Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases. Eur Respir J. 2020;56(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251245</ArticleId><ArticleId IdType="pubmed">32457198</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas M, et al. . A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax. 2010;65(5):442–448.</Citation><ArticleIdList><ArticleId IdType="pubmed">20435869</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharninghausen JC, et al. . Risk factors for indeterminate outcome on interferon gamma release assay in non-US-born persons screened for latent tuberculosis infection. Open Forum Infect Dis. 2018;5(3):ofy184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6104778</ArticleId><ArticleId IdType="pubmed">30151410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong SH, et al. . Effect of immunosuppressive therapy on interferon γ release assay for latent tuberculosis screening in patients with autoimmune diseases: a systematic review and meta-analysis. Thorax. 2016;71(1):64–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">26659461</ArticleId></ArticleIdList></Reference><Reference><Citation>Leipe J, et al. . Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876–2885.</Citation><ArticleIdList><ArticleId IdType="pubmed">20583102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelante T, et al. . IL‐23 and the Th17 pathway promote inflammation and impair antifungal immune resistance. Eur J Immunol. 2007;37(10):2695–2706.</Citation><ArticleIdList><ArticleId IdType="pubmed">17899546</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. J Intensive Care. 2020;8:1–10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7245646</ArticleId><ArticleId IdType="pubmed">32483488</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor SM, et al. . T‐cell responses and therapies against SARS‐CoV‐2 infection. Immunology. 2021;162(1):30–43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7730020</ArticleId><ArticleId IdType="pubmed">32935333</ArticleId></ArticleIdList></Reference><Reference><Citation>Solanich X, et al. . Clinical significance of indeterminate QuantiFERON-TB gold plus assay results in hospitalized COVID-19 patients with severe hyperinflammatory syndrome. J Clin Med. 2021;10(5):918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7956705</ArticleId><ArticleId IdType="pubmed">33652893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward JD, Cornaby C, Schmitz JL. Indeterminate QuantiFERON Gold Plus results reveal deficient interferon gamma responses in severely ill COVID-19 patients. J Clin Microbiol. 2021;59(10): e0081121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451425</ArticleId><ArticleId IdType="pubmed">34232708</ArticleId></ArticleIdList></Reference><Reference><Citation>Samprathi M, Jayashree M. Biomarkers in COVID-19: An up-to-date review. Front Pediatr. 2021;8:1–14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8042162</ArticleId><ArticleId IdType="pubmed">33859967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>